Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz +9 more
wiley +1 more source
Evaluación de un paciente con dolor epigástrico y hallazgos sincrónicos infrecuentes. [PDF]
Grove RL, Soloaga D, Spina JC.
europepmc +1 more source
Clinical Validation of Plasma p‐217tau in Neurological Diseases
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi +13 more
wiley +1 more source
[Anomalous origin of the left anterior descending artery from the right coronary artery: A case report]. [PDF]
González-Aguirre R +4 more
europepmc +1 more source
Los delitos de lesiones. Especial referencia a las lesiones al feto [PDF]
Suanzes Pérez, Fernando
core
A Depolarizing Leak in Sodium Bicarbonate Cotransporter NBCe1 Causes Brain Edema
ABSTRACT Objectives SLC4A4 encodes electrogenic sodium bicarbonate cotransporter NBCe1, prominently expressed in kidney and brain. Recessive loss‐of‐function variants in SLC4A4 cause proximal renal tubular acidosis, no brain edema. In the brain, NBCe1 is expressed by astrocytes, where it regulates pH and mediates astrocyte volume changes.
Quinty Bisseling +16 more
wiley +1 more source
[Prevalence of Helicobacter pylori and Endoscopic and Histopathological Fin-dings in Obese Patients who are Can-didates for Bariatric Surgery]. [PDF]
Martínez Ramírez RM +4 more
europepmc +1 more source
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source
[Palmoplantar pustulosis: A case report]. [PDF]
de Antonio Feu S +2 more
europepmc +1 more source
Risk Assessment Scale for the Development of Medical Adhesive-related Skin Injuries. [PDF]
Faria MF +5 more
europepmc +1 more source

